SLC5A2 and metabolic dysfunction-associated steatohepatitis: Newer antidiabetic drug classes, including glucagon-like peptide 1 (GLP1) receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors, have emerged as potential therapies for NASH.